Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H10NO2.Na |
| Molecular Weight | 187.171 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].N[C@@H](CC1=CC=CC=C1)C([O-])=O
InChI
InChIKey=ZRVUAXXSASAVFG-QRPNPIFTSA-M
InChI=1S/C9H11NO2.Na/c10-8(9(11)12)6-7-4-2-1-3-5-7;/h1-5,8H,6,10H2,(H,11,12);/q;+1/p-1/t8-;/m0./s1
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C9H10NO2 |
| Molecular Weight | 164.1812 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Phenylalanine is a biologically essential amino acid that acts as a precursor to tyrosine and the catecholamines (epinephrine, norepinephrine, dopamine, and tyramine), and is a constituent
of many central nervous system neuropeptides. Normal dietary levels of phenylalanine are approximately 1-2 grams daily. Phenylalanine appears in two forms which are identical mirror images of each other: L-phenylalanine, a nutritional supplement, and D-phenylalanine, an effective painkiller and antidepressant due to its ability to inhibit the breakdown of enkephalins, the brain’s natural pain killers.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3076 |
|||
Target ID: CHEMBL1907608 |
1.71 mM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | FREAMINE III 10% Approved UseParenteral nutrition with 8.5% FreAmine® III (Amino Acid Injection) with Electrolytes is
indicated to prevent nitrogen loss or treat negative nitrogen balance in adults and pediatric
patients, where (1) the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or
should not be used, or adequate protein intake is not feasible by these routes; (2) gastrointestinal
absorption of protein is impaired; or (3) protein requirements are substantially increased as with
extensive burns. Dosage, route of administration, and concomitant infusion of non-protein
calories are dependent on various factors, such as nutritional metabolic status of the patient, anticipated duration of parenteral nutritional support, and vein tolerance Launch Date1971 |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1389 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11244252/ |
20 mg/kg single, intravenous dose: 20 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PHENYLALANINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
35.7 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11244252/ |
20 mg/kg single, intravenous dose: 20 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PHENYLALANINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11244252/ |
20 mg/kg single, intravenous dose: 20 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PHENYLALANINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| L-amino acid sensing by the extracellular Ca2+-sensing receptor. | 2000 Apr 25 |
|
| Primary structure, functional characteristics and tissue expression pattern of human ATA2, a subtype of amino acid transport system A. | 2000 Jul 31 |
|
| Association between minihaplotypes and mutations at the PAH locus in Polish hyperphenylalaninemic patients. | 2001 |
|
| Self-association of the H3 region of syntaxin 1A. Implications for intermediates in SNARE complex assembly. | 2001 Apr 20 |
|
| Mutation analysis of phenylketonuria in Yamagata prefecture, Japan. | 2001 Feb |
|
| Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. | 2001 Feb |
|
| Pumping capacity of bacterial reaction centers and backpressure regulation of energy transduction. | 2001 Feb |
|
| Design, X-ray crystallography, molecular modelling and thermal stability studies of mutant enzymes at site 172 of 3-isopropylmalate dehydrogenase from Thermus thermophilus. | 2001 Feb |
|
| [A study of phenylketonuria heterozygotes screening in married population of Tianjin area]. | 2001 Feb |
|
| Tyrosine phosphorylation of p120(ctn) in v-Src transfected L cells depends on its association with E-cadherin and reduces adhesion activity. | 2001 Feb |
|
| Aldehyde dehydrogenase. Maintaining critical active site geometry at motif 8 in the class 3 enzyme. | 2001 Feb |
|
| Effects of the potent analgesic enkephalin-catabolizing enzyme inhibitors RB101 and kelatorphan on respiration. | 2001 Feb 1 |
|
| C-terminal elements control location, activation threshold, and p38 docking of ribosomal S6 kinase B (RSKB). | 2001 Feb 23 |
|
| Development of matrix metalloproteinase inhibitors in cancer therapy. | 2001 Feb 7 |
|
| Kynurenine aminotransferase I activity in human placenta. | 2001 Feb-Mar |
|
| Characterization of the mouse phenylalanine hydroxylase mutation Pah(enu3). | 2001 Jan |
|
| Net amino acid flux across the fetal liver and placenta during spontaneous ovine parturition. | 2001 Jan |
|
| The unique tryptophan residue of the vitamin D receptor is critical for ligand binding and transcriptional activation. | 2001 Jan |
|
| A study of peptide--peptide interaction by matrix-assisted laser desorption/ionization. | 2001 Jan |
|
| Single-stranded DNA intermediates in IS91 rolling-circle transposition. | 2001 Jan |
|
| Tyrosine phosphorylation of the beta 4 integrin cytoplasmic domain mediates Shc signaling to extracellular signal-regulated kinase and antagonizes formation of hemidesmosomes. | 2001 Jan 12 |
|
| Analysis of the subsite specificity of rat insulysin using fluorogenic peptide substrates. | 2001 Jan 12 |
|
| Development and de novo protein synthetic activity of bovine embryos produced in vitro in different culture systems. | 2001 Jan 15 |
|
| Amino acid phosphoramidate monoesters of 3'-azido-3'-deoxythymidine: relationship between antiviral potency and intracellular metabolism. | 2001 Jan 18 |
|
| A single arginyl residue in plastocyanin and in cytochrome c(6) from the cyanobacterium Anabaena sp. PCC 7119 is required for efficient reduction of photosystem I. | 2001 Jan 5 |
|
| Plasma free amino acid concentrations in healthy Guatemalan adults and in patients with classic dengue. | 2001 Mar |
|
| Complete loss of P/Q calcium channel activity caused by a CACNA1A missense mutation carried by patients with episodic ataxia type 2. | 2001 Mar |
|
| Spectral and metal-binding properties of three single-point tryptophan mutants of the human transferrin N-lobe. | 2001 Mar 1 |
|
| Evidence that phenylalanine 69 in Escherichia coli RuvC resolvase forms a stacking interaction during binding and destabilization of a Holliday junction DNA substrate. | 2001 Mar 30 |
Patents
Sample Use Guides
L-Phenylalanine Capsules (400 mg/cap): one to two capsules per day on an empty stomach.
L-Phenylalanine Powder: 480 mg one to two times per day on an empty stomach.
DL-Phenylalanine Capsules (500 mg/cap): one capsule daily on an empty stomach.
DL-Phenylalanine Powder: 1/8 level teaspoon two to three times daily on an empty stomach.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:58:53 GMT 2023
by
admin
on
Fri Dec 15 17:58:53 GMT 2023
|
| Record UNII |
M67R83MDEE
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DBSALT002207
Created by
admin on Fri Dec 15 17:58:53 GMT 2023 , Edited by admin on Fri Dec 15 17:58:53 GMT 2023
|
PRIMARY | |||
|
DTXSID10167810
Created by
admin on Fri Dec 15 17:58:53 GMT 2023 , Edited by admin on Fri Dec 15 17:58:53 GMT 2023
|
PRIMARY | |||
|
240-534-3
Created by
admin on Fri Dec 15 17:58:53 GMT 2023 , Edited by admin on Fri Dec 15 17:58:53 GMT 2023
|
PRIMARY | |||
|
23677936
Created by
admin on Fri Dec 15 17:58:53 GMT 2023 , Edited by admin on Fri Dec 15 17:58:53 GMT 2023
|
PRIMARY | |||
|
16480-57-2
Created by
admin on Fri Dec 15 17:58:53 GMT 2023 , Edited by admin on Fri Dec 15 17:58:53 GMT 2023
|
PRIMARY | |||
|
M67R83MDEE
Created by
admin on Fri Dec 15 17:58:53 GMT 2023 , Edited by admin on Fri Dec 15 17:58:53 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
